Trials / Terminated
TerminatedNCT00111306
Study of Epratuzumab in Systemic Lupus Erythematosus
A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 510 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epratuzumab |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2005-05-20
- Last updated
- 2011-11-08
Locations
18 sites across 6 countries: United States, Belgium, Hungary, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00111306. Inclusion in this directory is not an endorsement.